Softwr

Healthcare · head to head

Allscripts vs Paige

Allscripts logo

Allscripts

Healthcare

Healthcare IT solutions for care coordination

From
On request
Rated
-
Full reviewWebsite
Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Allscripts pricing is not publicly available; all quotes require direct contact with sales; Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • They diverge on capability: Allscripts covers Electronic Health Records, Paige covers Paige Prostate Detect.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Allscripts and Paige actually diverge.

Attributes where Allscripts and Paige differ
AttributeAllscriptsPaige
PlatformsWebWeb, Cloud, On-premise
Founded1986Unknown

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Allscripts

  • Electronic Health Records
  • Practice Management
  • Population Health
  • Care Coordination
  • Analytics
  • HL7
  • FHIR
  • Labs

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

What people use each for

The jobs each tool is most often brought in to do.

Allscripts

  • Electronic health records and practice management for healthcare providersnot Paige
  • Healthcare IT solutions for revenue cycle management and patient engagement (now Veradigm)not Paige

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot Allscripts
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot Allscripts
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot Allscripts
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot Allscripts

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Allscripts

  • Pricing is not publicly available; all quotes require direct contact with sales
  • Transitioned to Veradigm brand in 2022; legacy Allscripts product line integrated into Veradigm suite

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

Pricing, plan by plan

Allscripts

On request

No published plan breakdown. See the Allscripts review.

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

Which should you pick?

Choose Allscripts if

  • You need electronic health records.
  • You also want practice management.
Allscripts review

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Questions people ask

Is Allscripts or Paige better?
Neither clearly leads. Allscripts starts at On request and Paige at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Allscripts or Paige?
Allscripts starts at On request and Paige at On request.
Does Allscripts or Paige run on more platforms?
Allscripts runs on Web. Paige runs on Web, Cloud, On-premise.
What is Allscripts best used for?
Allscripts is most often used for electronic health records and practice management for healthcare providers, healthcare it solutions for revenue cycle management and patient engagement (now veradigm). Of those, electronic health records and practice management for healthcare providers and healthcare it solutions for revenue cycle management and patient engagement (now veradigm) are not what Paige is typically brought in for.
What can Allscripts do that Paige cannot?
Allscripts covers Electronic Health Records, Practice Management, Population Health, Care Coordination. Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications.

Answered from the vendors’ own pages

Allscripts: How do I obtain pricing information for Veradigm solutions?

Veradigm does not publish pricing on their website. Interested buyers must contact a Veradigm Account Executive directly or request a demo to discuss pricing and licensing options tailored to their needs.

Source
Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

Allscripts: What industries does Veradigm serve?

Veradigm serves four primary market segments: Healthcare Providers, Life Sciences companies, Health Plans and Payers, and Health IT Vendors. Each segment has specialized solutions.

Source
Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

Allscripts: Is there a trial available for Veradigm solutions?

Veradigm offers the option to request a demo of their solutions, which is the primary way potential customers can evaluate the platform before making a purchasing decision.

Source
Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Share

Related pages

More on Allscripts

More on Paige

Keep looking

Other head to heads